$40M up front: Skyhawk takes flight with Vertex deal

A busy, buzzy Vertex finds a high-profile partner in the RNA-drugging world to launch a fresh ...

Vertex joins Skyhawk’s roster of A-list partners, securing options on RNA splicing modulators

The Endpoints 11 : Here are some of the most promising startups in biotech. And Covid-19 isn’t ...

Skyhawk Therapeutics boosts Merck collab pact with added targets, upfront and biobucks

Skyhawk Therapeutics Announces Expansion of its Collaboration Agreement with Merck

Merck doubles down on Skyhawk’s tech to drug RNA, promising $600M per autoimmune, metabolic target

The 20 under 40 : Inside the next generation of biopharma leaders

Experienced Business Leader in Biopharmaceutical Industry Joins as Chief Operating Officer

The 20 Startups to Watch in Boston in 2020

Celgene execs shell out $92M cash for a pair of R&D deals that will fit perfectly in their new home

Skyhawk’s $80M Celgene deal expands remit to autoimmune

C&EN’s 2019 10 Start-Ups to Watch

Skyhawk Therapeutics Announces a Second Multi-Target Collaboration Agreement with Celgene

Fattening the bankroll, Bill Haney adds cancer R&D powerhouse Merck to Skyhawk’s roster

Bill Haney’s Skyhawk spears another marquee alliance for its work drugging RNA in Takeda neuro pact

Top 20 Life Science Startups to Watch in 2019

Biogen looks to expand neuro pipeline via C4, Skyhawk deals

Joining forces with Skyhawk, C4 Therapeutics, Biogen buys more shots on goal on SMA, Alzheimer’s

Skyhawk Announces Strategic Collaboration with Celgene to Discover and Develop Novel mRNA Splicing